

Werner Poewe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9272488/publications.pdf>

Version: 2024-02-01

623
papers

71,283
citations

870

117
h-index

850

244
g-index

684
all docs

684
docs citations

684
times ranked

38646
citing authors

#	ARTICLE	IF	CITATIONS
1	Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [¹¹ C]-PBR28 and Machine Learning Analysis. <i>Movement Disorders</i> , 2022, 37, 119-129.	2.2	18
2	Cardiac sympathetic innervation in Parkinson's disease versus multiple system atrophy. <i>Clinical Autonomic Research</i> , 2022, 32, 103-114.	1.4	7
3	Prodromal Parkinson's disease: hype or hope for disease-modification trials?. <i>Translational Neurodegeneration</i> , 2022, 11, 11.	3.6	21
4	Optimal deep brain stimulation sites and networks for cervical vs. generalized dystonia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2114985119.	3.3	26
5	Associations of Gait Disorders and Recurrent Falls in Older People: A Prospective Population-Based Study. <i>Gerontology</i> , 2022, 68, 1139-1144.	1.4	3
6	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 1131-1148.	2.2	222
7	How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?. <i>Movement Disorders</i> , 2022, 37, 1581-1592.	2.2	29
8	Effects of Nabilone on Sleep Outcomes in Patients with Parkinson's Disease: A Post-hoc Analysis of NMS Study. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 751-758.	0.8	10
9	Eye Tracking in Patients with Parkinson's Disease Treated with Nabilone—Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study. <i>Brain Sciences</i> , 2022, 12, 661.	1.1	4
10	Functional connectivity and topology in patients with restless legs syndrome: a case-control resting-state functional magnetic resonance imaging study. <i>European Journal of Neurology</i> , 2021, 28, 448-458.	1.7	24
11	Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 87-91.	1.1	16
12	Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 177-186.	1.5	33
13	Adapting to post-COVID19 research in Parkinson's disease: Lessons from a multinational experience. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 146-149.	1.1	7
14	Automated Analysis of Diffusion-Weighted Magnetic Resonance Imaging for the Differential Diagnosis of Multiple System Atrophy from Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 241-245.	2.2	15
15	Impaired Inhibitory Control of Saccadic Eye Movements in Cervical Dystonia: An Eye-Tracking Study. <i>Movement Disorders</i> , 2021, 36, 1246-1250.	2.2	2
16	Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement. <i>Clinical Autonomic Research</i> , 2021, 31, 157-164.	1.4	22
17	Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study. <i>Parkinsonism and Related Disorders</i> , 2021, 83, 79-85.	1.1	39
18	Application of the Updated Movement Disorder Society Criteria for Prodromal Parkinson's Disease to a Population-Based 10-Year Study. <i>Movement Disorders</i> , 2021, 36, 1464-1466.	2.2	11

#	ARTICLE	IF	CITATIONS
19	Rapid eye movement sleep behavior disorder and rapid eye movement sleep without atonia are more frequent in advanced versus early Parkinson's disease. <i>Sleep</i> , 2021, 44, .	0.6	16
20	Characterization and diagnostic potential of diffusion tractography in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2021, 85, 30-36.	1.1	8
21	Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder. <i>Brain</i> , 2021, 144, 1118-1126.	3.7	92
22	Challenges in the diagnosis of Parkinson's disease. <i>Lancet Neurology</i> , The, 2021, 20, 385-397.	4.9	468
23	Orthostatic Hypotension in Parkinson's Disease: Do Height and Weight Matter?. <i>Movement Disorders</i> , 2021, 36, 2703-2705.	2.2	1
24	On-Demand Therapy for OFF Episodes in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2244-2253.	2.2	16
25	Safety and Tolerability of Active Immunotherapy Targeting α -Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1079-1089.	1.5	29
26	Subcutaneous Levodopa Infusion for Parkinson's Disease: 1 Year Data from the Open-Label BeyoND Study. <i>Movement Disorders</i> , 2021, 36, 2687-2692.	2.2	20
27	Amantadine in the treatment of Parkinson's disease and other movement disorders. <i>Lancet Neurology</i> , The, 2021, 20, 1048-1056.	4.9	67
28	Efficacy of opicapone according to different levodopa daily intakes in Parkinson's disease patients with motor fluctuations. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119446.	0.3	0
29	Characterization of gait variability in multiple system atrophy and Parkinson's disease. <i>Journal of Neurology</i> , 2021, 268, 1770-1779.	1.8	18
30	A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. <i>Frontiers in Neurology</i> , 2021, 12, 705407.	1.1	36
31	The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II. <i>Frontiers in Neurology</i> , 2021, 12, 754016.	1.1	7
32	Identification of Restless Legs Syndrome Genes by Mutational Load Analysis. <i>Annals of Neurology</i> , 2020, 87, 184-193.	2.8	19
33	Midbrain hyperechogenicity, hyposmia, mild parkinsonian signs and risk for incident Parkinson's disease over 10 years: A prospective population-based study. <i>Parkinsonism and Related Disorders</i> , 2020, 70, 51-54.	1.1	23
34	Neurological research & training after the easing of lockdown in countries impacted by COVID-19. <i>Journal of the Neurological Sciences</i> , 2020, 418, 117105.	0.3	3
35	A Standardized MR Imaging Protocol for Parkinsonism. <i>Movement Disorders</i> , 2020, 35, 1745-1750.	2.2	7
36	Deep brain stimulation reduces (nocturnal) dyskinetic exacerbations in patients with ADCY5 mutation: a case series. <i>Journal of Neurology</i> , 2020, 267, 3624-3631.	1.8	15

#	ARTICLE	IF	CITATIONS
37	The Frontal Assessment Battery in RLS patients with and without augmentation. <i>Sleep Medicine</i> , 2020, 75, 456-458.	0.8	4
38	Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone. <i>Annals of Neurology</i> , 2020, 88, 712-722.	2.8	55
39	Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1816-1830.	1.7	23
40	Has Deep Brain Stimulation Changed the Very Long-Term Outcome of Parkinson's Disease? A Controlled Longitudinal Study. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 782-787.	0.8	11
41	Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease. <i>Neurology</i> , 2020, 95, e2854-e2865.	1.5	25
42	Long duration response in Parkinson's disease: levodopa revisited. <i>Brain</i> , 2020, 143, 2332-2335.	3.7	10
43	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 750-762.	0.8	31
44	Oleh Hornykiewicz (1926-2020). <i>Journal of Parkinson's Disease</i> , 2020, 10, 753-756.	1.5	0
45	A Phase 1 Randomized Trial of Specific Active α -Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy. <i>Movement Disorders</i> , 2020, 35, 1957-1965.	2.2	53
46	Augmentation in restless legs syndrome: an eye tracking study on emotion processing. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1620-1627.	1.7	8
47	Application of a Simple Parkinson's Disease Risk Score in a Longitudinal Population-Based Cohort. <i>Movement Disorders</i> , 2020, 35, 1658-1662.	2.2	11
48	Safety and immunogenicity of the α -synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial. <i>Lancet Neurology</i> , The, 2020, 19, 591-600.	4.9	83
49	Predictors of Response for Off-Time Improvement With Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis of the GLORIA Registry. <i>Frontiers in Neurology</i> , 2020, 11, 419.	1.1	3
50	Lack of Asymmetry of Nigrostriatal Dopaminergic Function in Healthy Subjects. <i>Movement Disorders</i> , 2020, 35, 1072-1076.	2.2	13
51	Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 57-63.	1.1	18
52	Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving 2000mg Daily Dose of Levodopa. <i>Parkinson's Disease</i> , 2020, 2020, 1-11.	0.6	8
53	Pharmacologic Treatment of Motor Symptoms Associated with Parkinson Disease. <i>Neurologic Clinics</i> , 2020, 38, 255-267.	0.8	34
54	Diagnostic potential of automated tractography in progressive supranuclear palsy variants. <i>Parkinsonism and Related Disorders</i> , 2020, 72, 65-71.	1.1	11

#	ARTICLE	IF	CITATIONS
55	Cognition in multiple system atrophy: a single-center cohort study. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 219-228.	1.7	31
56	No effect of age, gender and total intracranial volume on brainstem MR planimetric measurements. <i>European Radiology</i> , 2020, 30, 2802-2808.	2.3	5
57	Parkinson disease and the immune system – associations, mechanisms and therapeutics. <i>Nature Reviews Neurology</i> , 2020, 16, 303-318.	4.9	254
58	Multiomics Analyses Identify Genes and Pathways Relevant to Essential Tremor. <i>Movement Disorders</i> , 2020, 35, 1153-1162.	2.2	11
59	New hopes for disease modification in Parkinson's Disease. <i>Neuropharmacology</i> , 2020, 171, 108085.	2.0	25
60	Nighttime and morning OFF improvements with opicapone in patients with Parkinson's Disease and motor fluctuations: BIPARK-1 and BIPARK-2 pooled subanalyses. <i>Parkinsonism and Related Disorders</i> , 2020, 79, e53-e54.	1.1	1
61	Efficacy of opicapone in patients with Parkinson's disease with levodopa dose reduction: a pooled post-hoc analysis of BIPARK-I and II. <i>Parkinsonism and Related Disorders</i> , 2020, 79, e62-e63.	1.1	0
62	The neuropsychiatric phenotype in <i>CACNA1A</i> mutations: a retrospective single center study and review of the literature. <i>European Journal of Neurology</i> , 2019, 26, 66.	1.7	32
63	Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2019, 58, 23-27.	1.1	16
64	The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent α -synuclein in experimental multiple system atrophy. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 165513.	1.8	25
65	Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety. <i>Journal of Parkinson's Disease</i> , 2019, 9, 531-541.	1.5	30
66	Towards seeing the visual impairments in Parkinson's disease: protocol for a multicentre observational, cross-sectional study. <i>BMC Neurology</i> , 2019, 19, 141.	0.8	11
67	Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2019, 18, 724-735.	4.9	79
68	Urinary retention discriminates multiple system atrophy from Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1926-1928.	2.2	19
69	0673 Multimodal MRI Reveals Alterations Of Sensorimotor Circuits In Restless Legs Syndrome. <i>Sleep</i> , 2019, 42, A268-A270.	0.6	0
70	Physiotherapy improves motor function in patients with the Parkinson variant of multiple system atrophy: A prospective trial. <i>Parkinsonism and Related Disorders</i> , 2019, 67, 60-65.	1.1	23
71	Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations. <i>CNS Drugs</i> , 2019, 33, 905-918.	2.7	92
72	Diagnostic Potential of Multimodal MRI Markers in Atypical Parkinsonian Disorders. <i>Journal of Parkinson's Disease</i> , 2019, 9, 681-691.	1.5	15

#	ARTICLE	IF	CITATIONS
73	Safety Profile of Opicapone in the Management of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2019, 9, 733-740.	1.5	25
74	Multimodal Magnetic Resonance Imaging reveals alterations of sensorimotor circuits in restless legs syndrome. <i>Sleep</i> , 2019, 42, .	0.6	29
75	Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions. <i>European Journal of Neurology</i> , 2019, 26, 953-960.	1.7	41
76	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). <i>Parkinsonism and Related Disorders</i> , 2019, 62, 201-209.	1.1	15
77	Nabilone for non-motor symptoms of Parkinson's disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study). <i>Journal of Neural Transmission</i> , 2019, 126, 1061-1072.	1.4	16
78	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 975-984.	2.2	73
79	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 1228-1232.	2.2	93
80	Morphometric MRI profiles of multiple system atrophy variants and implications for differential diagnosis. <i>Movement Disorders</i> , 2019, 34, 1041-1048.	2.2	36
81	Probabilistic mapping of the antidystonic effect of pallidal neurostimulation: a multicentre imaging study. <i>Brain</i> , 2019, 142, 1386-1398.	3.7	105
82	Smelling Parkinson's Disease: New Metabolomic Biomarker for PD. <i>ACS Central Science</i> , 2019, 5, 575-576.	5.3	0
83	Early distinction of Parkinson's variant multiple system atrophy from Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 440-441.	2.2	21
84	Imaging markers of disease progression in multiple system atrophy. <i>Future Neurology</i> , 2019, 14, FNL24.	0.9	3
85	Effect of opicapone in Parkinson's disease patients with "early" motor fluctuations: Parkinson's disease questionnaire (PDQ-39) analysis from the BIPARK-I double-blind experience. <i>Journal of the Neurological Sciences</i> , 2019, 405, 190-191.	0.3	0
86	Efficacy of opicapone in Parkinson's disease patients with "early" motor fluctuations: Patient and clinical global impression of change from the BIPARK-I double-blind experience. <i>Journal of the Neurological Sciences</i> , 2019, 405, 191-192.	0.3	0
87	Incidence of treatment-emergent adverse events in Parkinson's Disease patients according to baseline body mass index: Post-hoc analysis from double-blind combined BIPARK-I and II data. <i>Journal of the Neurological Sciences</i> , 2019, 405, 200.	0.3	0
88	Efficacy of opicapone in Parkinson's disease patients according to baseline pramipexole use: A post-hoc analysis from combined BIPARK-I and II. <i>Journal of the Neurological Sciences</i> , 2019, 405, 192-193.	0.3	0
89	Opicapone as a levodopa sparing agent: Pooled analysis of BIPARK-I and II double-blind trials. <i>Journal of the Neurological Sciences</i> , 2019, 405, 218-219.	0.3	1
90	Efficacy of opicapone in Parkinson's disease patients according to baseline rasagiline use: A post-hoc analysis from combined BIPARK-I and II. <i>Journal of the Neurological Sciences</i> , 2019, 405, 193.	0.3	0

#	ARTICLE	IF	CITATIONS
91	Opicapone odds ratio in relative off-time reduction: A post-hoc analysis from combined BIPARK-I and II data. <i>Journal of the Neurological Sciences</i> , 2019, 405, 87-88.	0.3	1
92	Quality of life improvements in patients with cervical dystonia following treatment with a liquid formulation of abobotulinumtoxinA (Dysport [®]). <i>European Journal of Neurology</i> , 2019, 26, 943.	1.7	5
93	Prevalence and Associated Factors of Sarcopenia and Frailty in Parkinson's Disease: A Cross-Sectional Study. <i>Gerontology</i> , 2019, 65, 216-228.	1.4	63
94	Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry. <i>Neurodegenerative Disease Management</i> , 2019, 9, 39-46.	1.2	19
95	The role of exposure to pesticides in the etiology of Parkinson's disease: a 18F-DOPA positron emission tomography study. <i>Journal of Neural Transmission</i> , 2019, 126, 159-166.	1.4	2
96	Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence-based medicine review. <i>Movement Disorders</i> , 2019, 34, 180-198.	2.2	619
97	Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel. <i>European Journal of Neurology</i> , 2019, 26, 581.	1.7	23
98	The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2018, 54, 90-94.	1.1	49
99	Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson's disease. <i>Neurodegenerative Disease Management</i> , 2018, 8, 161-170.	1.2	13
100	The reorganization of functional architecture in the early-stages of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 50, 61-68.	1.1	64
101	Reflection impulsivity perceptual decision-making in patients with restless legs syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 315-322.	1.7	10
102	Diagnostic potential of dentatorubrothalamic tract analysis in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2018, 49, 81-87.	1.1	27
103	Performance of the Movement Disorders Society criteria for prodromal Parkinson's disease: A population-based 10-year study. <i>Movement Disorders</i> , 2018, 33, 405-413.	2.2	53
104	Autonomic function testing in spinocerebellar ataxia type 2. <i>Clinical Autonomic Research</i> , 2018, 28, 341-346.	1.4	13
105	Progressive striatonigral degeneration in a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies. <i>Acta Neuropathologica Communications</i> , 2018, 6, 2.	2.4	50
106	Clinical Rating Scales for Urinary Symptoms in Parkinson Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 479-491.	0.8	18
107	Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. <i>Parkinsonism and Related Disorders</i> , 2018, 52, 83-89.	1.1	46
108	Long-term efficacy of inhaled levodopa in Parkinson's disease subjects with motor fluctuations: Interim results of a phase 3 study. <i>Parkinsonism and Related Disorders</i> , 2018, 46, e19.	1.1	1

#	ARTICLE	IF	CITATIONS
109	Screening for idiopathic REM sleep behavior disorder: usefulness of actigraphy. <i>Sleep</i> , 2018, 41, .	0.6	38
110	MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSP. <i>Parkinsonism and Related Disorders</i> , 2018, 46, 47-55.	1.1	45
111	The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1460-1477.	1.7	330
112	Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine. <i>Movement Disorders</i> , 2018, 33, 1528-1539.	2.2	73
113	Region-Specific Effects of Immunotherapy With Antibodies Targeting α -synuclein in a Transgenic Model of Synucleinopathy. <i>Frontiers in Neuroscience</i> , 2018, 12, 452.	1.4	31
114	Neurostimulation in tardive dystonia/dyskinesia: A delayed start, sham stimulation-controlled randomized trial. <i>Brain Stimulation</i> , 2018, 11, 1368-1377.	0.7	35
115	Reader response: Olfaction and incident Parkinson disease in US white and black older adults. <i>Neurology</i> , 2018, 90, 940-940.	1.5	5
116	Autonomic function testing in Friedreich's ataxia. <i>Journal of Neurology</i> , 2018, 265, 2015-2022.	1.8	14
117	Motor and nonmotor complications of levodopa: phenomenology, risk factors, and imaging features. <i>Movement Disorders</i> , 2018, 33, 909-919.	2.2	89
118	Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , 2018, 17, 749-759.	4.9	203
119	Sensor-based gait analysis in atypical parkinsonian disorders. <i>Brain and Behavior</i> , 2018, 8, e00977.	1.0	43
120	Long-term pulmonary safety of inhaled levodopa in parkinsonian disease subjects with motor fluctuations: interim results of a phase 3 study. <i>Parkinsonism and Related Disorders</i> , 2018, 46, e83.	1.1	1
121	Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1643-1646.	2.2	114
122	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1601-1608.	2.2	171
123	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 33-40.	1.1	17
124	Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 619-623.	2.2	129
125	Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 536-544.	0.8	65
126	Ocular and visual disorders in Parkinson's disease: Common but frequently overlooked. <i>Parkinsonism and Related Disorders</i> , 2017, 40, 1-10.	1.1	110

#	ARTICLE	IF	CITATIONS
127	IgLON5 autoimmunity tested negative in patients with progressive supranuclear palsy and corticobasal syndrome. <i>Parkinsonism and Related Disorders</i> , 2017, 38, 102-103.	1.1	18
128	Consistency of "Probable RBD" Diagnosis with the RBD Screening Questionnaire: A Follow-up Study. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 403-405.	0.8	20
129	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017, 32, 853-864.	2.2	1,402
130	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. <i>Lancet Neurology</i> , The, 2017, 16, 701-711.	4.9	248
131	Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 649-659.	1.4	11
132	Gray matter abnormalities of the dorsal posterior cingulate in sleep walking. <i>Sleep Medicine</i> , 2017, 36, 152-155.	0.8	29
133	Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations. <i>JAMA Neurology</i> , 2017, 74, 197.	4.5	146
134	Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations. <i>JAMA Neurology</i> , 2017, 74, 216.	4.5	171
135	Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. <i>Parkinsonism and Related Disorders</i> , 2017, 45, 13-20.	1.1	149
136	Levodopa and Parkinson Disease "Myths Revisited. <i>JAMA Neurology</i> , 2017, 74, 1270.	4.5	7
137	Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis. <i>Lancet Neurology</i> , The, 2017, 16, 898-907.	4.9	191
138	Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. <i>Annals of Neurology</i> , 2017, 82, 419-428.	2.8	161
139	Molecular diversity of combined and complex dystonia: insights from diagnostic exome sequencing. <i>Neurogenetics</i> , 2017, 18, 195-205.	0.7	37
140	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. <i>Movement Disorders</i> , 2017, 32, 1264-1310.	2.2	608
141	Response to: On the role of visual electrophysiology in parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 45, 98.	1.1	0
142	Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study. <i>Movement Disorders</i> , 2017, 32, 1457-1464.	2.2	60
143	Insulin signalling: new target for Parkinson's treatments?. <i>Lancet</i> , The, 2017, 390, 1628-1630.	6.3	4
144	Franz Gerstenbrand - Obituary. <i>European Journal of Neurology</i> , 2017, 24, 1089-1090.	1.7	0

#	ARTICLE	IF	CITATIONS
145	Brain structural profile of multiple system atrophy patients with cognitive impairment. <i>Journal of Neural Transmission</i> , 2017, 124, 293-302.	1.4	46
146	Pharmacogenetics of Parkinson's Disease in Clinical Practice. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 173-180.	0.8	13
147	Clinical exome sequencing in early-onset generalized dystonia and large-scale resequencing follow-up. <i>Movement Disorders</i> , 2017, 32, 549-559.	2.2	94
148	Sniffing the diagnosis: Olfactory testing in neurodegenerative parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2017, 35, 36-41.	1.1	67
149	Topography of Dopamine Transporter Availability in the Cerebellar Variant of Multiple System Atrophy. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 389-396.	0.8	4
150	Caveats of Neurodegenerative Risk Stratification in Idiopathic REM Sleep Behavior Disorder by Use of the MDS Research for Prodromal Parkinson's Disease. <i>Sleep</i> , 2017, 40, .	0.6	5
151	SOX5-Null Heterozygous Mutation in a Family with Adult-Onset Hyperkinesia and Behavioral Abnormalities. <i>Case Reports in Genetics</i> , 2017, 2017, 1-6.	0.1	4
152	Diffusion-weighted MRI distinguishes Parkinson disease from the parkinsonian variant of multiple system atrophy: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0189897.	1.1	44
153	Haste makes waste: Decision making in patients with restless legs syndrome with and without augmentation. <i>PLoS ONE</i> , 2017, 12, e0174793.	1.1	14
154	Influence of a Post-Test Factor on the Results of the Multiple Sleep Latency Test. <i>Journal of Clinical Sleep Medicine</i> , 2016, 12, 529-531.	1.4	3
155	Subjective Visual Vertical in PD Patients with Lateral Trunk Flexion. <i>Parkinson's Disease</i> , 2016, 2016, 1-4.	0.6	16
156	Changes in the miRNA-mRNA Regulatory Network Precede Motor Symptoms in a Mouse Model of Multiple System Atrophy: Clinical Implications. <i>PLoS ONE</i> , 2016, 11, e0150705.	1.1	26
157	Elastic Abdominal Binders Attenuate Orthostatic Hypotension in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 156-160.	0.8	35
158	Clinical Heterogeneity in Cerebral Hemiatrophy Syndromes. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 382-388.	0.8	5
159	Neuropathological criteria of anti-IgLON5-related tauopathy. <i>Acta Neuropathologica</i> , 2016, 132, 531-543.	3.9	173
160	Substantia nigra hyperechogenicity and Parkinson's disease risk in patients with essential tremor. <i>Movement Disorders</i> , 2016, 31, 579-583.	2.2	17
161	Mavoglurant in Parkinson's patients with Dopa-induced dyskinesias: Two randomized phase 2 studies. <i>Movement Disorders</i> , 2016, 31, 1054-1058.	2.2	55
162	Prodromal Parkinson's disease as defined per MDS research criteria in the general elderly community. <i>Movement Disorders</i> , 2016, 31, 1405-1408.	2.2	71

#	ARTICLE	IF	CITATIONS
163	Loss of dorsolateral nigral hyperintensity on 3.0 tesla susceptibility-weighted imaging in idiopathic rapid eye movement sleep behavior disorder. <i>Annals of Neurology</i> , 2016, 79, 1026-1030.	2.8	90
164	Minimally clinically important decline in the parkinsonian variant of multiple system atrophy. <i>Movement Disorders</i> , 2016, 31, 1577-1581.	2.2	14
165	Apomorphine and levodopa in Parkinson's disease: Two revolutionary drugs from the 1950's. <i>Parkinsonism and Related Disorders</i> , 2016, 33, S9-S12.	1.1	23
166	Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism. <i>Neurology</i> , 2016, 86, 1242-1249.	1.5	89
167	The new definition and diagnostic criteria of Parkinson's disease. <i>Lancet Neurology</i> , The, 2016, 15, 546-548.	4.9	82
168	Abolishing the 1-year rule: How much evidence will be enough?. <i>Movement Disorders</i> , 2016, 31, 1623-1627.	2.2	43
169	Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial. <i>Movement Disorders</i> , 2016, 31, 1649-1657.	2.2	35
170	Systematic TOR1A non-c.907_909delGAG variant analysis in isolated dystonia and controls. <i>Parkinsonism and Related Disorders</i> , 2016, 31, 119-123.	1.1	4
171	Eldad Melamed 1942-2015: Ave atque-A memorial. <i>Movement Disorders</i> , 2016, 31, 39-40.	2.2	0
172	Optimizing odor identification testing as quick and accurate diagnostic tool for Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1408-1413.	2.2	55
173	Haploinsufficiency of KMT2B, Encoding the Lysine-Specific Histone Methyltransferase 2B, Results in Early-Onset Generalized Dystonia. <i>American Journal of Human Genetics</i> , 2016, 99, 1377-1387.	2.6	135
174	1.5 Versus 3 tesla magnetic resonance planimetry in neurodegenerative parkinsonism. <i>Movement Disorders</i> , 2016, 31, 1925-1927.	2.2	8
175	Genome-wide association study in essential tremor identifies three new loci. <i>Brain</i> , 2016, 139, 3163-3169.	3.7	78
176	Utility of Nigral Signal Intensity Changes on MR Images to Differentiate Drug-induced Parkinsonism from Parkinson Disease. <i>Radiology</i> , 2016, 281, 651-652.	3.6	1
177	Reply to letter: Nonmotor symptoms in subjects without evidence of dopaminergic deficits. <i>Movement Disorders</i> , 2016, 31, 1588-1589.	2.2	0
178	Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage. <i>Journal of Parkinson's Disease</i> , 2016, 6, 741-749.	1.5	13
179	Reply to "Nonmotor symptoms in subjects without evidence of dopaminergic deficit" authors: "Swallow DMA, Grosset KA, Grosset DG". <i>Movement Disorders</i> , 2016, 31, 430-431.	2.2	0
180	Neuroprotection by Epigenetic Modulation in a Transgenic Model of Multiple System Atrophy. <i>Neurotherapeutics</i> , 2016, 13, 871-879.	2.1	17

#	ARTICLE	IF	CITATIONS
181	The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. <i>Journal of Neural Transmission</i> , 2016, 123, 439-445.	1.4	32
182	Supine hypertension in Parkinson's disease and multiple system atrophy. <i>Clinical Autonomic Research</i> , 2016, 26, 97-105.	1.4	87
183	The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 2016, 39, 88-93.	0.2	3
184	<i>Banisteriopsis caapi</i> , a Forgotten Potential Therapy for Parkinson's Disease?. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 19-26.	0.8	19
185	Levodopa-carbidopa intestinal gel treatment in patients with < 10 years of Parkinson's disease: GLORIA registry interim results. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e93-e94.	1.1	0
186	Gastrointestinal safety of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients: GLORIA long-term registry interim results. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e96-e97.	1.1	0
187	Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. <i>Lancet Neurology</i> , The, 2016, 15, 154-165.	4.9	219
188	MDS research criteria for prodromal Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1600-1611.	2.2	1,033
189	The Concept of Prodromal Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 681-697.	1.5	195
190	Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits. <i>Movement Disorders</i> , 2015, 30, 1885-1892.	2.2	52
191	Plasma fasting cholesterol profiles and age at onset in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1974-1975.	2.2	7
192	Probable RBD and association with neurodegenerative disease markers: A population-based study. <i>Movement Disorders</i> , 2015, 30, 1417-1421.	2.2	86
193	Preface. <i>Movement Disorders</i> , 2015, 30, 1441-1441.	2.2	0
194	A Prospective Video-Polysomnographic Analysis of Movements during Physiological Sleep in 100 Healthy Sleepers. <i>Sleep</i> , 2015, 38, 1479-1487.	0.6	34
195	Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism. <i>Movement Disorders</i> , 2015, 30, 1068-1076.	2.2	125
196	Nonmotor symptoms in subjects without evidence of dopaminergic deficits. <i>Movement Disorders</i> , 2015, 30, 976-981.	2.2	32
197	Invasive Treatment Strategies in a Patient with PARK-15 Associated Parkinsonism. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 434-435.	0.8	1
198	Therapeutic advances in multiple system atrophy and progressive supranuclear palsy. <i>Movement Disorders</i> , 2015, 30, 1528-1538.	2.2	17

#	ARTICLE	IF	CITATIONS
199	Involvement of Peripheral Nerves in the Transgenic PLP- α -Syn Model of Multiple System Atrophy: Extending the Phenotype. PLoS ONE, 2015, 10, e0136575.	1.1	17
200	Potential of Diffusion Tensor Imaging and Relaxometry for the Detection of Specific Pathological Alterations in Parkinson's Disease (PD). PLoS ONE, 2015, 10, e0145493.	1.1	14
201	Impact of Impulse Control Disorders on Sleep-Wake Regulation in Parkinson's Disease. Parkinson's Disease, 2015, 2015, 1-7.	0.6	8
202	Long-Term Follow-up Investigation of Isolated Rapid Eye Movement Sleep Without Atonia Without Rapid Eye Movement Sleep Behavior Disorder: A Pilot Study. Journal of Clinical Sleep Medicine, 2015, 11, 1273-1279.	1.4	75
203	MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders, 2015, 30, 1591-1601.	2.2	4,389
204	Cognitive outcome of pallidal deep brain stimulation for primary cervical dystonia: One year follow up results of a prospective multicenter trial. Parkinsonism and Related Disorders, 2015, 21, 976-980.	1.1	24
205	Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. Parkinsonism and Related Disorders, 2015, 21, 231-235.	1.1	118
206	Diagnostic value of the REM sleep behavior disorder screening questionnaire in Parkinson's disease. Sleep Medicine, 2015, 16, 186-189.	0.8	86
207	Predictors for mild parkinsonian signs: A prospective population-based study. Parkinsonism and Related Disorders, 2015, 21, 321-324.	1.1	27
208	Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. Lancet Neurology, The, 2015, 14, 145-152.	4.9	90
209	Multiple system atrophy—new insight from prospective studies. Nature Reviews Neurology, 2015, 11, 430-431.	4.9	2
210	Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. Parkinsonism and Related Disorders, 2015, 21, 1133-1144.	1.1	156
211	IgLON5 autoimmunity and abnormal behaviours during sleep. Lancet, The, 2015, 385, 1590.	6.3	49
212	Mortality in Parkinson's disease: A 38-year follow-up study. Movement Disorders, 2015, 30, 266-269.	2.2	95
213	Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS. Movement Disorders, 2015, 30, 589-592.	2.2	22
214	Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off. Journal of Neural Transmission, 2015, 122, 1709-1714.	1.4	19
215	Asian perspectives on the recognition and management of levodopa "wearing-off" in Parkinson's disease. Expert Review of Neurotherapeutics, 2015, 15, 1285-1297.	1.4	22
216	Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease "Clinical practice recommendations. Parkinsonism and Related Disorders, 2015, 21, 1023-1030.	1.1	126

#	ARTICLE	IF	CITATIONS
217	Reply: Nonmotor symptoms in subjects without evidence of dopaminergic deficits. <i>Movement Disorders</i> , 2015, 30, 1437-1438.	2.2	1
218	Enteric nervous system α -synuclein immunoreactivity in idiopathic REM sleep behavior disorder. <i>Neurology</i> , 2015, 85, 1761-1768.	1.5	121
219	Natural course of restless legs syndrome/Willis-Ekbom disease: long-term observation of a large clinical cohort. <i>Sleep Medicine</i> , 2015, 16, 1252-1258.	0.8	29
220	Alpha-synuclein immunoreactivity patterns in the enteric nervous system. <i>Neuroscience Letters</i> , 2015, 602, 145-149.	1.0	40
221	Large-scale TUBB4A mutational screening in isolated dystonia and controls. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1278-1281.	1.1	7
222	Failure of Neuroprotection Despite Microglial Suppression by Delayed-Start Myeloperoxidase Inhibition in a Model of Advanced Multiple System Atrophy: Clinical Implications. <i>Neurotoxicity Research</i> , 2015, 28, 185-194.	1.3	38
223	Cerebral autoregulation and white matter lesions in Parkinson's disease and multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1393-1397.	1.1	33
224	Thrombolysis and clinical outcome in patients with stroke after implementation of the Tyrol Stroke Pathway: a retrospective observational study. <i>Lancet Neurology</i> , The, 2015, 14, 48-56.	4.9	53
225	Levodopa: 50 years of a revolutionary drug for Parkinson disease. <i>Movement Disorders</i> , 2015, 30, 1-3.	2.2	47
226	Novel formulations and modes of delivery of levodopa. <i>Movement Disorders</i> , 2015, 30, 114-120.	2.2	76
227	The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study). <i>Movement Disorders</i> , 2015, 30, 229-237.	2.2	402
228	Movement Disorders in Systemic Diseases. <i>Neurologic Clinics</i> , 2015, 33, 269-297.	0.8	13
229	I15 Sleep In Patients With Huntington's Disease: Interim Results From A Polysomnographic Study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, A63-A63.	0.9	0
230	Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release. <i>Parkinson's Disease</i> , 2014, 2014, 1-8.	0.6	51
231	Perimenstrual Fluctuations in Two Siblings With Early-Onset Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 125-127.	0.8	3
232	Long-term Safety of Rivastigmine in Parkinson Disease Dementia. <i>Clinical Neuropharmacology</i> , 2014, 37, 9-16.	0.2	62
233	Quantitative assessment of isolated rapid eye movement (REM) sleep without atonia without clinical REM sleep behavior disorder: clinical and research implications. <i>Sleep Medicine</i> , 2014, 15, 1009-1015.	0.8	31
234	Towards translational therapies for multiple system atrophy. <i>Progress in Neurobiology</i> , 2014, 118, 19-35.	2.8	35

#	ARTICLE	IF	CITATIONS
235	Rifampicin for multiple system atrophy. <i>Lancet Neurology, The</i> , 2014, 13, 237-239.	4.9	3
236	VPS35 Parkinson's disease phenotype resembles the sporadic disease. <i>Journal of Neural Transmission</i> , 2014, 121, 755-759.	1.4	42
237	Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMS) study group. <i>Movement Disorders</i> , 2014, 29, 857-867.	2.2	193
238	Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease. <i>European Journal of Neurology</i> , 2014, 21, 736-743.	1.7	31
239	Movement disorders: new insights into disease mechanisms and treatment. <i>Lancet Neurology, The</i> , 2014, 13, 9-11.	4.9	6
240	Risk factors and prodromal markers and the development of Parkinson's disease. <i>Journal of Neurology</i> , 2014, 261, 180-187.	1.8	38
241	Vertical supranuclear gaze palsy induced by deep brain stimulation: Report of two cases. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1295-1297.	1.1	3
242	Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial. <i>Lancet Neurology, The</i> , 2014, 13, 875-884.	4.9	281
243	Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 169-176.	2.2	15
244	Adenosine A2A receptor antagonists in Parkinson's disease: still in the running. <i>Lancet Neurology, The</i> , 2014, 13, 748-749.	4.9	18
245	Episodic ataxia type 2: phenotype characteristics of a novel CACNA1A mutation and review of the literature. <i>Journal of Neurology</i> , 2014, 261, 983-991.	1.8	49
246	Detecting nocturnal hypertension in Parkinson's disease and multiple system atrophy: proposal of a decision-support algorithm. <i>Journal of Neurology</i> , 2014, 261, 1291-1299.	1.8	47
247	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 454-462.	2.2	379
248	Low Bone Mineral Density in Friedreich Ataxia. <i>Cerebellum</i> , 2014, 13, 549-557.	1.4	13
249	Is there a polysomnographic signature of augmentation in restless legs syndrome?. <i>Sleep Medicine</i> , 2014, 15, 1231-1240.	0.8	11
250	Intestinal levodopa infusion in PD—the first randomized trial. <i>Nature Reviews Neurology</i> , 2014, 10, 128-129.	4.9	9
251	Poster 155 Dysport®, AbobotulinumtoxinA, is Effective with a Favorable Safety Profile in the Treatment of Cervical Dystonia: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study. <i>PM and R</i> , 2014, 6, S238-S239.	0.9	0
252	Poster 156 Dysport®, AbobotulinumtoxinA, Improves Disease-Specific Quality of Life in Patients with Cervical Dystonia, as Measured by Patient-Reported Outcomes, in a Phase III, Randomized, Double-Blind, Placebo-Controlled Study. <i>PM and R</i> , 2014, 6, S239.	0.9	0

#	ARTICLE	IF	CITATIONS
253	Multiple system atrophy as emerging template for accelerated drug discovery in α -synucleinopathies. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 793-799.	1.1	18
254	Validation of an Integrated Software for the Detection of Rapid Eye Movement Sleep Behavior Disorder. <i>Sleep</i> , 2014, 37, 1663-1671.	0.6	61
255	Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder. <i>Movement Disorders</i> , 2014, 29, 1774-1780.	2.2	74
256	A Prospective Questionnaire Study in 100 Healthy Sleepers: Non-Bothersome Forms of Recognizable Sleep Disorders Are Still Present. <i>Journal of Clinical Sleep Medicine</i> , 2014, 10, 623-629.	1.4	28
257	Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 50-56.	1.7	22
258	Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. <i>Journal of Neurology</i> , 2013, 260, 2701-2714.	1.8	128
259	Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care. <i>Journal of Neural Transmission</i> , 2013, 120, 1553-1558.	1.4	59
260	A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type. <i>Journal of Neural Transmission</i> , 2013, 120, 613-618.	1.4	75
261	Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1064-1071.	2.2	374
262	Diagnosis of drug-induced parkinsonism: can transcranial sonography make the difference?. <i>European Journal of Neurology</i> , 2013, 20, 1429-1430.	1.7	3
263	AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. <i>Movement Disorders</i> , 2013, 28, 1838-1846.	2.2	122
264	The natural history of multiple system atrophy: a prospective European cohort study. <i>Lancet Neurology</i> , The, 2013, 12, 264-274.	4.9	426
265	Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 5-15.	1.7	290
266	EFNS/MDS-ES recommendations for the diagnosis of Parkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 16-34.	1.7	460
267	The PRIPS study: screening battery for subjects at risk for Parkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 102-108.	1.7	113
268	Success rate, efficacy, and safety/tolerability of overnight switching from immediate to extended-release pramipexole in advanced Parkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 180-187.	1.7	12
269	Toll-like receptor 4 is required for α -synuclein dependent activation of microglia and astroglia. <i>Glia</i> , 2013, 61, 349-360.	2.5	542
270	Risk of dyskinesia in Parkinson's disease patients who already have developed wearing-off: A secondary analysis of STRIDE-PD study. <i>Journal of the Neurological Sciences</i> , 2013, 333, e65-e66.	0.3	0

#	ARTICLE	IF	CITATIONS
271	Nonmotor symptoms in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 581-583.	1.4	15
272	Management of Motor and Non-Motor Symptoms in Parkinson's Disease. <i>CNS Drugs</i> , 2013, 27, 259-272.	2.7	66
273	Defining premotor Parkinson's disease: a window of opportunity for neuroprotection?. <i>Neurodegenerative Disease Management</i> , 2013, 3, 61-70.	1.2	2
274	Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. <i>Lancet Neurology</i> , The, 2013, 12, 514-524.	4.9	126
275	Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER. <i>Journal of Neural Transmission</i> , 2013, 120, 1069-1081.	1.4	55
276	On Polysomnography reveals unexpectedly high rates of organic sleep disorders in patients with prediagnosed primary insomnia (Sleep Breath 2011 doi 10.1007/s11325-011-0608-8). <i>Sleep and Breathing</i> , 2013, 17, 1-2.	0.9	3
277	Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. <i>Lancet Neurology</i> , The, 2013, 12, 747-755.	4.9	175
278	Substantia Nigra Hyperechogenicity as a Marker for Parkinson's Disease: A Population-Based Study. <i>Neurodegenerative Diseases</i> , 2013, 12, 212-218.	0.8	28
279	Trial designs used to study neuroprotective therapy in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 86-95.	2.2	59
280	Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease. <i>Brain</i> , 2013, 136, 3028-3037.	3.7	52
281	No association of GBA mutations and multiple system atrophy. <i>European Journal of Neurology</i> , 2013, 20, e61-2.	1.7	28
282	Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 216-219.	2.2	112
283	Which dyskinesia scale best detects treatment response?. <i>Movement Disorders</i> , 2013, 28, 341-346.	2.2	76
284	Intact Olfaction in a Mouse Model of Multiple System Atrophy. <i>PLoS ONE</i> , 2013, 8, e64625.	1.1	20
285	Prevalence and Burden of Gait Disorders in Elderly Men and Women Aged 60-97 Years: A Population-Based Study. <i>PLoS ONE</i> , 2013, 8, e69627.	1.1	151
286	Delayed Diagnosis, Range of Severity, and Multiple Sleep Comorbidities: A Clinical and Polysomnographic Analysis of 100 Patients of the Innsbruck Narcolepsy Cohort. <i>Journal of Clinical Sleep Medicine</i> , 2013, 09, 805-812.	1.4	90
287	Bioenergetics of the Calf Muscle in Friedreich Ataxia Patients Measured by 31P-MRS Before and After Treatment with Recombinant Human Erythropoietin. <i>PLoS ONE</i> , 2013, 8, e69229.	1.1	22
288	Therapies in Parkinson's disease. <i>Current Opinion in Neurology</i> , 2012, 25, 433-447.	1.8	180

#	ARTICLE	IF	CITATIONS
289	Emerging therapies for Parkinson's disease. <i>Current Opinion in Neurology</i> , 2012, 25, 448-459.	1.8	51
290	Efficacy and Safety of Extended- Versus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-dopa-Undertreated Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2012, 35, 174-181.	0.2	30
291	Skeletal Muscle Involvement in Friedreich Ataxia and Potential Effects of Recombinant Human Erythropoietin Administration on Muscle Regeneration and Neovascularization. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 708-715.	0.9	37
292	Normative EMG Values during REM Sleep for the Diagnosis of REM Sleep Behavior Disorder. <i>Sleep</i> , 2012, 35, 835-847.	0.6	332
293	Decision Making and Executive Functions in REM Sleep Behavior Disorder. <i>Sleep</i> , 2012, 35, 667-673.	0.6	43
294	The Unified Multiple System Atrophy Rating Scale: Intrarater reliability. <i>Movement Disorders</i> , 2012, 27, 1683-1685.	2.2	18
295	Validation of the Innsbruck REM sleep behavior disorder inventory. <i>Movement Disorders</i> , 2012, 27, 1673-1678.	2.2	87
296	Combined assessment of midbrain hyperechogenicity, hyposmia and motor asymmetry improves diagnostic accuracy in early Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 911-914.	1.4	7
297	Left hemispheric predominance of nigrostriatal dysfunction in Parkinson's disease. <i>Brain</i> , 2012, 135, 3348-3354.	3.7	95
298	An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes. <i>Proteome Science</i> , 2012, 10, 71.	0.7	22
299	Pallidal deep brain stimulation in patients with primary generalised or segmental dystonia: 5-year follow-up of a randomised trial. <i>Lancet Neurology</i> , The, 2012, 11, 1029-1038.	4.9	329
300	Drug safety evaluation of rotigotine. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 503-512.	1.0	17
301	Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease. <i>Clinical Interventions in Aging</i> , 2012, 7, 83.	1.3	13
302	LO1...Sleep in patients with huntington's disease: an interim analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, A43.3-A43.	0.9	3
303	White and Gray Matter Abnormalities in Narcolepsy with Cataplexy. <i>Sleep</i> , 2012, 35, 345-351.	0.6	46
304	Defining at-risk populations for Parkinson's disease: Lessons from ongoing studies. <i>Movement Disorders</i> , 2012, 27, 656-665.	2.2	113
305	Can we define "pre-motor" Parkinson's disease?. <i>Movement Disorders</i> , 2012, 27, 595-596.	2.2	5
306	Is transcranial sonography useful to distinguish drug-induced parkinsonism from Parkinson's disease?. <i>Movement Disorders</i> , 2012, 27, 1194-1196.	2.2	17

#	ARTICLE	IF	CITATIONS
307	A follow-up study of substantia nigra echogenicity in healthy adults. <i>Movement Disorders</i> , 2012, 27, 1196-1197.	2.2	17
308	Is transcranial sonography useful to distinguish scans without evidence of dopaminergic deficit patients from Parkinson's disease?. <i>Movement Disorders</i> , 2012, 27, 1182-1185.	2.2	32
309	Orthostatic Hypotension Is Differentially Associated with the Cerebellar Versus the Parkinsonian Variant of Multiple System Atrophy: a Comparative Study. <i>Cerebellum</i> , 2012, 11, 223-226.	1.4	22
310	Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α -synuclein under oligodendrocyte promoter: implications for multiple system atrophy. <i>Acta Neuropathologica</i> , 2012, 124, 51-65.	3.9	73
311	Investigation of autonomic function in idiopathic REM sleep behavior disorder. <i>Journal of Neurology</i> , 2012, 259, 1056-1061.	1.8	64
312	Can observers link dream content to behaviours in rapid eye movement sleep behaviour disorder? A cross-sectional experimental pilot study. <i>Journal of Sleep Research</i> , 2012, 21, 21-29.	1.7	46
313	Premotor signs and symptoms of multiple system atrophy. <i>Lancet Neurology</i> , The, 2012, 11, 361-368.	4.9	201
314	Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 284-288.	2.2	68
315	Substantia nigra hypoechogenicity in Friedreich ataxia. <i>Movement Disorders</i> , 2012, 27, 332-333.	2.2	5
316	Taking sides: Is handedness involved in motor asymmetry of Parkinson's disease?. <i>Movement Disorders</i> , 2012, 27, 171-173.	2.2	18
317	Myeloperoxidase Inhibition Ameliorates Multiple System Atrophy-Like Degeneration in a Transgenic Mouse Model. <i>Neurotoxicity Research</i> , 2012, 21, 393-404.	1.3	96
318	The scale for the assessment and rating of ataxia correlates with dysarthria assessment in Friedreich's ataxia. <i>Journal of Neurology</i> , 2012, 259, 420-426.	1.8	31
319	Toll-Like Receptor 4 Promotes α -Synuclein Clearance and Survival of Nigral Dopaminergic Neurons. <i>American Journal of Pathology</i> , 2011, 179, 954-963.	1.9	230
320	Usefulness of the SINBAR electromyographic montage to detect the motor and vocal manifestations occurring in REM sleep behavior disorder. <i>Sleep Medicine</i> , 2011, 12, 284-288.	0.8	91
321	Fragmentary myoclonus in sleep revisited: A polysomnographic study in 62 patients. <i>Sleep Medicine</i> , 2011, 12, 410-415.	0.8	35
322	Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome. <i>Sleep Medicine</i> , 2011, 12, 351-360.	0.8	74
323	Costs of illness and care in Parkinson's Disease: An evaluation in six countries. <i>European Neuropsychopharmacology</i> , 2011, 21, 180-191.	0.3	84
324	New insights into atypical parkinsonism. <i>Current Opinion in Neurology</i> , 2011, 24, 331-338.	1.8	27

#	ARTICLE	IF	CITATIONS
325	Excessive Daytime Sleepiness in Multiple System Atrophy (SLEEMSA Study). Archives of Neurology, 2011, 68, 223-30.	4.9	83
326	Motor disturbances during non-REM and REM sleep in narcolepsy-cataplexy: a video-polysomnographic analysis. Journal of Sleep Research, 2011, 20, 514-521.	1.7	29
327	A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurology, The, 2011, 10, 415-423.	4.9	192
328	Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurology, The, 2011, 10, 710-720.	4.9	133
329	Pramipexole extended release in Parkinson's disease. Expert Review of Neurotherapeutics, 2011, 11, 1229-1234.	1.4	6
330	Extended-release pramipexole in early Parkinson disease. Neurology, 2011, 77, 759-766.	1.5	83
331	A Mutation in VPS35, Encoding a Subunit of the Retromer Complex, Causes Late-Onset Parkinson Disease. American Journal of Human Genetics, 2011, 89, 168-175.	2.6	757
332	Effects of Erythropoietin on Frataxin Levels and Mitochondrial Function in Friedreich Ataxia – a Dose-Response Trial. Cerebellum, 2011, 10, 763-769.	1.4	34
333	Restless legs syndrome in Friedreich ataxia: A polysomnographic study. Movement Disorders, 2011, 26, 302-306.	2.2	13
334	Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double-blind, randomized, placebo-controlled study (RECOVER). Movement Disorders, 2011, 26, 90-99.	2.2	394
335	Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy. Movement Disorders, 2011, 26, 507-515.	2.2	17
336	Axial myopathy in parkinsonism. Movement Disorders, 2011, 26, 1569-1571.	2.2	6
337	Decades of delayed diagnosis in 4 levodopa-responsive young-onset monogenetic parkinsonism patients. Movement Disorders, 2011, 26, 1337-1340.	2.2	4
338	Milestones in Parkinson's disease therapeutics. Movement Disorders, 2011, 26, 1072-1082.	2.2	162
339	The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension. Movement Disorders, 2011, 26, 1985-1992.	2.2	52
340	Correlation of frataxin content in blood and skeletal muscle endorses frataxin as a biomarker in Friedreich ataxia. Movement Disorders, 2011, 26, 1935-1938.	2.2	33
341	Health-related quality of life scales in Parkinson's disease: Critique and recommendations. Movement Disorders, 2011, 26, 2371-2380.	2.2	234
342	Wearing off scales in Parkinson's disease: Critique and recommendations. Movement Disorders, 2011, 26, 2169-2175.	2.2	101

#	ARTICLE	IF	CITATIONS
343	White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: A diffusion-tensor imaging and voxel-based morphometry study. <i>Annals of Neurology</i> , 2011, 69, 400-407.	2.8	203
344	Extended-release pramipexole in advanced Parkinson disease. <i>Neurology</i> , 2011, 77, 767-774.	1.5	97
345	Enlarged Substantia Nigra Hyperechogenicity and Risk for Parkinson Disease. <i>Archives of Neurology</i> , 2011, 68, 932.	4.9	146
346	Genome-Wide Association Study Identifies Novel Restless Legs Syndrome Susceptibility Loci on 2p14 and 16q12.1. <i>PLoS Genetics</i> , 2011, 7, e1002171.	1.5	163
347	Levodopa in the treatment of Parkinson's disease: an old drug still going strong. <i>Clinical Interventions in Aging</i> , 2010, 5, 229.	1.3	194
348	A Descriptive Analysis of Neck Myoclonus During Routine Polysomnography. <i>Sleep</i> , 2010, 33, 1091-1096.	0.6	30
349	Social and clinical determinants of quality of life in Parkinson's disease in Austria: a cohort study. <i>Journal of Neurology</i> , 2010, 257, 638-645.	1.8	53
350	Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2010, 117, 1395-1399.	1.4	42
351	Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2010, 9, 573-580.	4.9	476
352	Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. <i>Lancet Neurology</i> , The, 2010, 9, 1070-1077.	4.9	349
353	Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study. <i>Annals of Neurology</i> , 2010, 68, 18-27.	2.8	330
354	Minocycline 1-year therapy in multiple system atrophy: Effect on clinical symptoms and [¹¹ C]-(R)-PK11195 PET (MEMSA trial). <i>Movement Disorders</i> , 2010, 25, 97-107.	2.2	163
355	Mortality in Parkinson's disease, a 20-year follow-up study. <i>Movement Disorders</i> , 2010, 25, 661-662.	2.2	41
356	Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study. <i>Movement Disorders</i> , 2010, 25, 896-905.	2.2	63
357	Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 805-822.	2.2	193
358	Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1357-1363.	2.2	159
359	Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2010, 25, 1131-1142.	2.2	90
360	Teaching program for the movement disorder society-sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS-UPDRS). <i>Movement Disorders</i> , 2010, 25, 1190-1194.	2.2	48

#	ARTICLE	IF	CITATIONS
361	Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly. <i>Movement Disorders</i> , 2010, 25, 1464-1469.	2.2	45
362	Reply: "Restless Legs Syndrome and Parkinson's Disease". <i>Movement Disorders</i> , 2010, 25, 1314-1315.	2.2	0
363	Rationale for delayed-start study of pramipexole in Parkinson's disease: The PROUD study. <i>Movement Disorders</i> , 2010, 25, 1627-1632.	2.2	38
364	Scales to assess sleep impairment in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2010, 25, 2704-2716.	2.2	214
365	Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry. <i>Movement Disorders</i> , 2010, 25, 2604-2612.	2.2	205
366	Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2326-2332.	2.2	36
367	Brain stem pathology in Parkinson's disease: An evaluation of the Braak staging model. <i>Movement Disorders</i> , 2010, 25, 2508-2515.	2.2	117
368	Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2542-2549.	2.2	87
369	Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrain-to-pontine area ratio to differentiate progressive supranuclear palsy from Parkinson's disease and the Parkinson variant of multiple system atrophy. <i>Movement Disorders</i> , 2010, 25, 2444-2449.	2.2	74
370	Treatment of the nonmotor symptoms of Parkinson disease. <i>Nature Reviews Neurology</i> , 2010, 6, 417-418.	4.9	12
371	Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: A randomized, placebo-controlled polysomnographic study. <i>Sleep Medicine</i> , 2010, 11, 848-856.	0.8	86
372	Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation. <i>Journal of Hepatology</i> , 2010, 53, 1101-1107.	1.8	74
373	REM sleep behavior disorder in 703 sleep-disorder patients: The importance of eliciting a comprehensive sleep history. <i>Sleep Medicine</i> , 2010, 11, 167-171.	0.8	75
374	Replication of restless legs syndrome loci in three European populations. <i>Journal of Medical Genetics</i> , 2009, 46, 315-318.	1.5	78
375	Austria. <i>Practical Neurology</i> , 2009, 9, 298-301.	0.5	2
376	Decision making under risk and under ambiguity in Parkinson's disease. <i>Neuropsychologia</i> , 2009, 47, 1901-1908.	0.7	65
377	Striatal transplantation in a rodent model of multiple system atrophy: Effects on L-Dopa response. <i>Journal of Neuroscience Research</i> , 2009, 87, 1679-1685.	1.3	23
378	Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder. <i>Movement Disorders</i> , 2009, 24, 1906-1909.	2.2	91

#	ARTICLE	IF	CITATIONS
379	Clinical measures of progression in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, S671-6.	2.2	77
380	Levodopa in the treatment of Parkinson's disease. <i>European Journal of Neurology</i> , 2009, 16, 982-989.	1.7	163
381	Perspectives on recent advances in the understanding and treatment of Parkinson's disease. <i>European Journal of Neurology</i> , 2009, 16, 1090-1099.	1.7	64
382	Prevalence of Primary Headaches and Cranial Neuralgias in Men and Women Aged 55-94 Years (Bruneck). <i>Tijdschrift voor Neurologie</i> , 2009, 10, 100-107.	1.8	77
383	A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease. <i>New England Journal of Medicine</i> , 2009, 361, 1268-1278.	13.9	830
384	P1.11 Dysautonomia Rating Scales in Parkinson's disease: Symptoms of orthostatic hypotension. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2009, 149, 63.	1.4	0
385	Mode of vagus nerve stimulation differentially affects sleep related breathing in patients with epilepsy. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2009, 18, 339-342.	0.9	30
386	The relation between abnormal behaviors and REM sleep microstructure in patients with REM sleep behavior disorder. <i>Sleep Medicine</i> , 2009, 10, 174-181.	0.8	46
387	PLM detection by actigraphy compared to polysomnography: A validation and comparison of two actigraphs. <i>Sleep Medicine</i> , 2009, 10, 306-311.	0.8	45
388	The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: Association with ferritin levels. <i>Sleep Medicine</i> , 2009, 10, 611-615.	0.8	96
389	Cerebral vasoreactivity decreases overnight in severe obstructive sleep apnea syndrome: A study of cerebral hemodynamics. <i>Sleep Medicine</i> , 2009, 10, 875-881.	0.8	56
390	Regional differences in the severity of Lewy body pathology across the olfactory cortex. <i>Neuroscience Letters</i> , 2009, 453, 77-80.	1.0	110
391	Periodic leg movements during sleep and periodic limb movement disorder in patients presenting with unexplained insomnia. <i>Clinical Neurophysiology</i> , 2009, 120, 257-263.	0.7	64
392	P2.152 Changes in early-morning motor status following adjunctive treatment of advanced Parkinson's disease with rotigotine transdermal system: two large, placebo-controlled trials. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S130-S131.	1.1	2
393	Pallidal deep brain stimulation improves quality of life in segmental and generalized dystonia: Results from a prospective, randomized sham-controlled trial. <i>Movement Disorders</i> , 2008, 23, 131-134.	2.2	131
394	Red flags for multiple system atrophy. <i>Movement Disorders</i> , 2008, 23, 1093-1099.	2.2	215
395	Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: A clinical pilot trial. <i>Movement Disorders</i> , 2008, 23, 1940-1944.	2.2	89
396	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. <i>Movement Disorders</i> , 2008, 23, 2129-2170.	2.2	4,796

#	ARTICLE	IF	CITATIONS
397	Diagnosis and management of Parkinson's disease dementia. International Journal of Clinical Practice, 2008, 62, 1581-1587.	0.8	77
398	PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nature Genetics, 2008, 40, 946-948.	9.4	252
399	Non-motor symptoms in Parkinson's disease. European Journal of Neurology, 2008, 15, 14-20.	1.7	524
400	Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2008, 7, 595-604.	4.9	195
401	Effects of Rivastigmine on Tremor and Other Motor Symptoms in Patients with Parkinson's Disease Dementia. Drug Safety, 2008, 31, 79-94.	1.4	44
402	Botulinum Toxin for Treatment of Dystonia. , 2008, , 227-240.		1
403	Second consensus statement on the diagnosis of multiple system atrophy. Neurology, 2008, 71, 670-676.	1.5	2,720
404	Safety of prolonged sacral neuromodulation tined lead testing. Current Medical Research and Opinion, 2008, 24, 343-347.	0.9	41
405	When a Parkinson's disease patient starts to hallucinate. Practical Neurology, 2008, 8, 238-241.	0.5	48
406	Chorea. , 2008, , 317-330.		1
407	Tesofensine (NS 2330), a Monoamine Reuptake Inhibitor, in Patients With Advanced Parkinson Disease and Motor Fluctuations. Archives of Neurology, 2008, 65, 577.	4.9	32
408	Physiology of Parkinson's Disease. , 2008, , 25-36.		9
409	General Management Approach to Dystonia. , 2008, , 217-226.		2
410	Surgical Treatments of Dystonia. , 2008, , 241-250.		0
411	Cramps and Spasms. , 2008, , 263-281.		0
412	Stiff Person Syndrome. , 2008, , 283-291.		0
413	The Etiopathogenesis of Parkinson's Disease: Basic Mechanisms of Neurodegeneration. , 2008, , 1-23.		0
414	Essential Tremor. , 2008, , 177-191.		1

#	ARTICLE	IF	CITATIONS
415	Other Tremor Disorders. , 2008, , 193-202.		0
416	Pathophysiology of Dystonia. , 2008, , 203-215.		1
417	Pharmacology of Parkinson's Disease. , 2008, , 37-48.		1
418	The Treatment of Early Parkinson's Disease. , 2008, , 49-70.		1
419	Treatment of Motor Complications in Advanced Parkinson's Disease. , 2008, , 71-90.		0
420	Managing the Non-Motor Symptoms of Parkinson's Disease. , 2008, , 91-120.		2
421	Surgery for Parkinson's Disease. , 2008, , 121-143.		2
422	Future Cell- and Gene-Based Therapies for Parkinson's Disease. , 2008, , 145-156.		0
423	Parkinson-Plus Disorders. , 2008, , 157-175.		1
424	Huntington's Disease. , 2008, , 293-315.		0
425	Treatment of Tics and Tourette Syndrome. , 2008, , 331-344.		0
426	Therapeutics of Paroxysmal Dyskinesias. , 2008, , 345-352.		0
427	Treatment of Miscellaneous Disorders. , 2008, , 353-362.		0
428	Myoclonus. , 2008, , 363-370.		2
429	Neuroleptic-Induced Movement Disorders. , 2008, , 371-387.		0
430	Other Drug-Induced Dyskinesias. , 2008, , 389-403.		0
431	Ataxia. , 2008, , 405-415.		0
432	Treatment of Gait and Balance Disorders. , 2008, , 417-443.		3

#	ARTICLE	IF	CITATIONS
433	The Restless Legs Syndrome. , 2008, , 445-467.		0
434	Pediatric Movement Disorders. , 2008, , 469-476.		0
435	Psychogenic Movement Disorders. , 2008, , 477-488.		0
436	Quantification of Electromyographic Activity During REM Sleep in Multiple Muscles in REM Sleep Behavior Disorder. Sleep, 2008, 31, 724-731.	0.6	160
437	Entscheiden bei Morbus Parkinson " eine "bersicht. Zeitschrift f"r Neuropsychologie = Journal of Neuropsychology, 2008, 19, 235-251.	0.2	0
438	Auditory Startle Reaction is disinhibited in idiopathic Restless Legs Syndrome. Sleep, 2007, 30, 489-493.	0.6	29
439	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Movement Disorders, 2007, 22, 41-47.	2.2	1,097
440	Depression rating scales in Parkinson's disease: Critique and recommendations. Movement Disorders, 2007, 22, 1077-1092.	2.2	583
441	Safety and tolerability of growth hormone therapy in multiple system atrophy: A double-blind, placebo-controlled study. Movement Disorders, 2007, 22, 1138-1144.	2.2	66
442	Clinical diagnostic criteria for dementia associated with Parkinson's disease. Movement Disorders, 2007, 22, 1689-1707.	2.2	2,497
443	Video analysis of motor events in REM sleep behavior disorder. Movement Disorders, 2007, 22, 1464-1470.	2.2	121
444	Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Movement Disorders, 2007, 22, 2409-2417.	2.2	221
445	Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force. Movement Disorders, 2007, 22, 2314-2324.	2.2	885
446	Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment. European Journal of Neurology, 2007, 14, 66-72.	1.7	37
447	Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurology, The, 2007, 6, 826-829.	4.9	231
448	High dose levodopa therapy is not toxic in multiple system atrophy: Experimental evidence. Movement Disorders, 2007, 22, 969-973.	2.2	6
449	Orthostatic hypotension and attention in Parkinson's disease with and without dementia. Journal of Neural Transmission, 2007, 114, 585-588.	1.4	65
450	Progression of brain atrophy in multiple system atrophy. Journal of Neurology, 2007, 254, 191-196.	1.8	108

#	ARTICLE	IF	CITATIONS
451	Depression in Parkinson's disease. <i>Journal of Neurology</i> , 2007, 254, 49-55.	1.8	34
452	Progression of putaminal degeneration in multiple system atrophy: A serial diffusion MR study. <i>NeuroImage</i> , 2006, 31, 240-245.	2.1	98
453	Parkinson's disease and arithmetics: The role of executive functions. <i>Journal of the Neurological Sciences</i> , 2006, 248, 124-130.	0.3	32
454	A Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease. <i>New England Journal of Medicine</i> , 2006, 355, 896-908.	13.9	2,577
455	Periodic limb movement counting in polysomnography: Effects of amplitude. <i>Sleep Medicine</i> , 2006, 7, 249-254.	0.8	11
456	Restless legs syndrome and motor activity during sleep in spinocerebellar ataxia type 6. <i>Sleep Medicine</i> , 2006, 7, 529-532.	0.8	35
457	Transient and permanent magnetic resonance imaging abnormalities after complex partial status epilepticus. <i>Epilepsy and Behavior</i> , 2006, 8, 666-671.	0.9	49
458	Topography of Dopamine Transporter Availability in Progressive Supranuclear Palsy. <i>Archives of Neurology</i> , 2006, 63, 1154.	4.9	59
459	Placebo-controlled trial of riluzole in multiple system atrophy. <i>European Journal of Neurology</i> , 2006, 13, 1146-1148.	1.7	32
460	Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. <i>European Journal of Neurology</i> , 2006, 13, 1186-1202.	1.7	183
461	Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain. <i>Journal of Neurology</i> , 2006, 253, 1337-1341.	1.8	153
462	The diagnosis of Parkinson's disease. <i>Lancet Neurology</i> , The, 2006, 5, 75-86.	4.9	665
463	Seminar on choreas. <i>Lancet Neurology</i> , The, 2006, 5, 589-602.	4.9	282
464	Cortical atrophy in the cerebellar variant of multiple system atrophy: A voxel-based morphometry study. <i>Movement Disorders</i> , 2006, 21, 159-165.	2.2	67
465	Progression of multiple system atrophy (MSA): A prospective natural history study by the European MSA Study Group (EMSA SG). <i>Movement Disorders</i> , 2006, 21, 179-186.	2.2	126
466	Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study. <i>Movement Disorders</i> , 2006, 21, 456-461.	2.2	109
467	Health-related quality of life in multiple system atrophy. <i>Movement Disorders</i> , 2006, 21, 809-815.	2.2	102
468	Topography of putaminal degeneration in multiple system atrophy: A diffusion magnetic resonance study. <i>Movement Disorders</i> , 2006, 21, 847-852.	2.2	62

#	ARTICLE	IF	CITATIONS
469	Minimal clinically important change on the unified Parkinson's disease rating scale. <i>Movement Disorders</i> , 2006, 21, 1200-1207.	2.2	253
470	Disturbance of rapid eye movement sleep in spinocerebellar ataxia type 2. <i>Movement Disorders</i> , 2006, 21, 1751-1754.	2.2	60
471	Social stigmatization in patients with cranial and cervical dystonia. <i>Movement Disorders</i> , 2006, 21, 1636-1640.	2.2	29
472	Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. <i>Brain</i> , 2006, 129, 538-542.	3.7	120
473	Neurological Outcome of Septic Cardioembolic Stroke After Infective Endocarditis. <i>Stroke</i> , 2006, 37, 2094-2099.	1.0	234
474	Pallidal Deep-Brain Stimulation in Primary Generalized or Segmental Dystonia. <i>New England Journal of Medicine</i> , 2006, 355, 1978-1990.	13.9	980
475	Daytime sleepiness and the COMT val158met polymorphism in patients with Parkinson disease. <i>Sleep</i> , 2006, 29, 108-11.	0.6	21
476	Urinary albumin excretion is independently associated with carotid and femoral artery atherosclerosis in the general population. <i>European Heart Journal</i> , 2005, 26, 279-287.	1.0	60
477	Animal models of multiple system atrophy. <i>Trends in Neurosciences</i> , 2005, 28, 501-506.	4.2	77
478	Computerized Tremor Analysis of Valproate-induced Tremor: A Comparative Study of Controlled-release versus Conventional Valproate. <i>Epilepsia</i> , 2005, 46, 320-323.	2.6	37
479	Prevalence of movement disorders in men and women aged 50-89 years (Bruneck Study cohort): a population-based study. <i>Lancet Neurology</i> , The, 2005, 4, 815-820.	4.9	271
480	Treatment of dementia with Lewy bodies and Parkinson's disease dementia. <i>Movement Disorders</i> , 2005, 20, S77-S82.	2.2	37
481	Failure of caspase inhibition in the double-lesion rat model of striatonigral degeneration (multiple) Tj ETQq1 1 0.784314 rgBT ₉ Overlo	3.9	39
482	Progression of parkinsonism in multiple system atrophy. <i>Journal of Neurology</i> , 2005, 252, 91-96.	1.8	55
483	Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy). <i>Journal of Neural Transmission</i> , 2005, 112, 1025-1033.	1.4	34
484	The European Multiple System Atrophy-Study Group (EMSA-SG). <i>Journal of Neural Transmission</i> , 2005, 112, 1677-1686.	1.4	75
485	How to diagnose MSA early: the role of magnetic resonance imaging. <i>Journal of Neural Transmission</i> , 2005, 112, 1625-1634.	1.4	54
486	Voxel-wise analysis of [123I]β ² -CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. <i>Brain</i> , 2005, 128, 1605-1612.	3.7	115

#	ARTICLE	IF	CITATIONS
487	Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. <i>Lancet, The</i> , 2005, 365, 947-954.	6.3	601
488	Prevalence and incidence of Parkinson's disease in Europe. <i>European Neuropsychopharmacology</i> , 2005, 15, 473-490.	0.3	461
489	Evaluation of [¹²³ I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats. <i>NeuroImage</i> , 2005, 24, 822-831.	2.1	24
490	Evidence for dopaminergic re-innervation by embryonic allografts in an optimized rat model of the Parkinsonian variant of multiple system atrophy. <i>Brain Research Bulletin</i> , 2005, 68, 54-58.	1.4	11
491	Oxidative Stress in Transgenic Mice with Oligodendroglial α -Synuclein Overexpression Replicates the Characteristic Neuropathology of Multiple System Atrophy. <i>American Journal of Pathology</i> , 2005, 166, 869-876.	1.9	191
492	Voxel-based morphometry in narcolepsy. <i>Sleep Medicine</i> , 2005, 6, 531-536.	0.8	76
493	Daytime sleepiness is not increased in mild to moderate multiple sclerosis: a pupillographic study. <i>Sleep Medicine</i> , 2005, 6, 543-547.	0.8	21
494	Clinical studies with transdermal rotigotine in early Parkinson's disease. <i>Neurology</i> , 2005, 65, S11-4.	1.5	31
495	Association of Daytime Sleepiness with COMT Polymorphism in Patients with Parkinson Disease: a Pilot Study. <i>Sleep</i> , 2004, 27, 733-736.	0.6	39
496	Osteoprotegerin Is a Risk Factor for Progressive Atherosclerosis and Cardiovascular Disease. <i>Circulation</i> , 2004, 109, 2175-2180.	1.6	466
497	Postural hand tremor before and following liver transplantation and immunosuppression with cyclosporine or tacrolimus in patients without clinical signs of hepatic encephalopathy. <i>Clinical Transplantation</i> , 2004, 18, 429-433.	0.8	17
498	Number processing and basal ganglia dysfunction: a single case study. <i>Neuropsychologia</i> , 2004, 42, 1050-1062.	0.7	70
499	Multiple system atrophy. <i>Lancet Neurology, The</i> , 2004, 3, 93-103.	4.9	443
500	Linguistic and neuropsychological deficits in crossed conduction aphasia. Report of three cases. <i>Brain and Language</i> , 2004, 88, 83-95.	0.8	16
501	Parkinsonism following striatal infarcts: incidence in a prospective stroke unit cohort. <i>Journal of Neural Transmission</i> , 2004, 111, 1473-1483.	1.4	44
502	Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration. <i>Journal of Neuroscience Research</i> , 2004, 78, 87-91.	1.3	28
503	Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease. <i>Movement Disorders</i> , 2004, 19, 1020-1028.	2.2	1,739
504	Comparison of diffusion-weighted imaging and [¹²³ I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease. <i>Movement Disorders</i> , 2004, 19, 1438-1445.	2.2	86

#	ARTICLE	IF	CITATIONS
505	Levodopa in the treatment of Parkinson's disease: Current controversies. <i>Movement Disorders</i> , 2004, 19, 997-1005.	2.2	331
506	Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). <i>Movement Disorders</i> , 2004, 19, 1391-1402.	2.2	481
507	Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy). <i>Neurobiology of Disease</i> , 2004, 15, 630-639.	2.1	28
508	Rivastigmine for Dementia Associated with Parkinson's Disease. <i>New England Journal of Medicine</i> , 2004, 351, 2509-2518.	13.9	1,111
509	Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease. <i>NeuroImage</i> , 2004, 21, 1443-1451.	2.1	149
510	Basal forebrain atrophy is a distinctive pattern in dementia with Lewy bodies. <i>NeuroReport</i> , 2004, 15, 1711-1714.	0.6	40
511	Neuropsychologische Befunde bei Stimulation der Basalganglien - ein Review. <i>Zeitschrift für Neuropsychologie = Journal of Neuropsychology</i> , 2004, 15, 287-301.	0.2	0
512	Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system) <i>Tj ETQq0 0 0 rgBT /Oxerlock 10 If 50 457</i>		
513	Evoked potentials in a case of progressive multifocal leukoencephalopathy. <i>Journal of Neurology</i> , 2003, 250, 236-238.	1.8	1
514	Acute double-blind, placebo-controlled sleep laboratory and clinical follow-up studies with a combination treatment of rr-L-dopa and sr-L-dopa in restless legs syndrome. <i>Journal of Neural Transmission</i> , 2003, 110, 611-626.	1.4	56
515	Medial temporal lobe activation during semantic language processing: fMRI findings in healthy left- and right-handers. <i>Cognitive Brain Research</i> , 2003, 17, 339-346.	3.3	61
516	Tumor necrosis factor- γ -induced cell death in U373 cells overexpressing γ -synuclein. <i>Journal of Neuroscience Research</i> , 2003, 73, 334-340.	1.3	37
517	Increased daytime sleepiness in Parkinson's disease: A questionnaire survey. <i>Movement Disorders</i> , 2003, 18, 319-323.	2.2	70
518	The γ -risus sardonicus? of multiple system atrophy. <i>Movement Disorders</i> , 2003, 18, 1211-1211.	2.2	25
519	Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy. <i>Movement Disorders</i> , 2003, 18, 1132-1138.	2.2	153
520	Distal myasthenia gravis - frequency and clinical course in a large prospective series. <i>Acta Neurologica Scandinavica</i> , 2003, 108, 209-211.	1.0	29
521	Elastin Polymorphism Haplotype and Intracranial Aneurysms Are Not Associated in Central Europe. <i>Stroke</i> , 2003, 34, 1207-1211.	1.0	53
522	Atrophy pattern in SCA2 determined by voxel-based morphometry. <i>NeuroReport</i> , 2003, 14, 1799-1802.	0.6	87

#	ARTICLE	IF	CITATIONS
523	Active and Passive Smoking, Chronic Infections, and the Risk of Carotid Atherosclerosis. <i>Stroke</i> , 2002, 33, 2170-2176.	1.0	97
524	Modafinil for the Treatment of Daytime Sleepiness in Parkinson's Disease: A Double-blind, Randomized, Crossover, Placebo-controlled Polygraphic Trial. <i>Sleep</i> , 2002, 25, 62-66.	0.6	216
525	Treatment interventions for Parkinson's disease: an evidence based assessment. <i>Lancet</i> , 2002, 359, 1589-1598.	6.3	266
526	Evaluation of Striatal Dopamine Transporter Function in Rats by in Vivo 123 I-CIT Pinhole SPECT. <i>NeuroImage</i> , 2002, 17, 128-141.	2.1	49
527	Parkinsonism in multiple system atrophy: Natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease. <i>Movement Disorders</i> , 2002, 17, 701-709.	2.2	76
528	Riluzole therapy in cervical dystonia. <i>Movement Disorders</i> , 2002, 17, 198-200.	2.2	28
529	Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2002, 109, 329-339.	1.4	250
530	The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. <i>Journal of Neurology</i> , 2002, 249, 842-846.	1.8	180
531	Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. <i>Journal of Neurology</i> , 2002, 249, 300-304.	1.8	74
532	Temporal Profile and Cell Subtype Distribution of Activated Caspase-3 Following Experimental Traumatic Brain Injury. <i>Journal of Neurochemistry</i> , 2002, 75, 1264-1273.	2.1	142
533	Low concentrations of STI571 in the cerebrospinal fluid: a case report. <i>British Journal of Haematology</i> , 2002, 117, 623-625.	1.2	90
534	Increased Expression of Apolipoprotein D Following Experimental Traumatic Brain Injury. <i>Journal of Neurochemistry</i> , 2002, 73, 1615-1625.	2.1	65
535	Early consolidation in human primary motor cortex. <i>Nature</i> , 2002, 415, 640-644.	13.7	720
536	No functional effects of embryonic neuronal grafts on motor deficits in a 3-nitropropionic acid rat model of advanced striatonigral degeneration (multiple system atrophy). <i>Neuroscience</i> , 2001, 102, 581-592.	1.1	34
537	Prognostic Value of Intraventricular Blood in Perimesencephalic Nonaneurysmal Subarachnoid Hemorrhage. <i>Journal of Computer Assisted Tomography</i> , 2001, 25, 742-746.	0.5	12
538	Riluzole in Huntington's disease (HD): an open label study with one year follow up. <i>Journal of Neurology</i> , 2001, 248, 866-869.	1.8	71
539	Clinical characteristics of the geste antagoniste in cervical dystonia. <i>Journal of Neurology</i> , 2001, 248, 478-482.	1.8	96
540	Temporal and spatial profile of caspase 8 expression and proteolysis after experimental traumatic brain injury. <i>Journal of Neurochemistry</i> , 2001, 78, 862-873.	2.1	59

#	ARTICLE	IF	CITATIONS
541	Juvenile asymmetric segmental spinal muscular atrophy (Hirayama's disease) Three cases without evidence of "flexion myelopathy". Acta Neurologica Scandinavica, 2001, 104, 320-322.	1.0	50
542	Glial cell death induced by overexpression of ?-synuclein. Journal of Neuroscience Research, 2001, 65, 432-438.	1.3	87
543	Intrafamilial heterogeneity of facial hyperkinesias: Chance association of tics, cranial dystonia, and Huntington's disease?. Movement Disorders, 2001, 16, 370-372.	2.2	5
544	Dynamic balance function in phasic cervical dystonia following Botulinum toxin therapy. Movement Disorders, 2001, 16, 934-937.	2.2	7
545	Irresistible onset of sleep during acute levodopa challenge in a patient with multiple system atrophy (MSA): Placebo-controlled, polysomnographic case report. Movement Disorders, 2001, 16, 1177-1179.	2.2	19
546	Apoptosis signals in sporadic amyotrophic lateral sclerosis: an immunocytochemical study. Acta Neuropathologica, 2001, 102, 426-434.	3.9	17
547	Efficacy and safety of a standardised 500 unit dose of Dysport Â® (Clostridium botulinum toxin type A) Tj ETQq1 1 0.784314 rgBT / Over multicentre, randomised, double-blind, placebo-controlled, parallel group study. Journal of Neurology, 2001, 248, 1073-1078.	1.8	79
548	Progression of Dysarthria and Dysphagia in Postmortem-Confirmed Parkinsonian Disorders. Archives of Neurology, 2001, 58, 259.	4.9	375
549	Chronic Infections and the Risk of Carotid Atherosclerosis. Circulation, 2001, 103, 1064-1070.	1.6	491
550	Simple assessments of mobility. Methodology and clinical application of kinetic gait analysis. Advances in Neurology, 2001, 87, 101-10.	0.8	1
551	Depression in Parkinson's disease. An update. Advances in Neurology, 2001, 86, 373-83.	0.8	37
552	Towards Neurotransplantation in Multiple System Atrophy: Clinical Rationale, Pathophysiological Basis, and Preliminary Experimental Evidence. Cell Transplantation, 2000, 9, 279-288.	1.2	37
553	Parkinson's disease and sleep. Current Opinion in Neurology, 2000, 13, 423-426.	1.8	43
554	Progressive multifocal leukoencephalopathy presenting with an isolated focal movement disorder. Movement Disorders, 2000, 15, 1006-1009.	2.2	16
555	Apomorphine: An underutilized therapy for Parkinson's disease. Movement Disorders, 2000, 15, 789-794.	2.2	127
556	Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Movement Disorders, 2000, 15, 873-878.	2.2	200
557	Quantification of sensory trick impact on tremor amplitude and frequency in 60 patients with head tremor. Movement Disorders, 2000, 15, 960-964.	2.2	46
558	Expression of Fas and Fas Ligand After Experimental Traumatic Brain Injury in the Rat. Journal of Cerebral Blood Flow and Metabolism, 2000, 20, 669-677.	2.4	118

#	ARTICLE	IF	CITATIONS
559	Management of Spasticity Associated Pain with Botulinum Toxin A. <i>Journal of Pain and Symptom Management</i> , 2000, 20, 44-49.	0.6	184
560	Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a SPET study using ¹²³ I-β-CIT and ¹²³ I-β-BZM. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 1410-1414.	2.2	125
561	Complex motor disturbances in a sequential double lesion rat model of striatonigral degeneration (multiple system atrophy). <i>Neuroscience</i> , 2000, 99, 43-54.	1.1	55
562	In Vivo Magnetic Resonance Imaging of Embryonic Neural Grafts in a Rat Model of Striatonigral Degeneration (Multiple System Atrophy). <i>NeuroImage</i> , 2000, 12, 209-218.	2.1	12
563	A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Compare the Efficacy and Safety of Three Doses of Botulinum Toxin Type A (Dysport) With Placebo in Upper Limb Spasticity After Stroke. <i>Stroke</i> , 2000, 31, 2402-2406.	1.0	280
564	Botulinum Toxin A in the Management of Spastic Gait Disorders in Children and Young Adults with Cerebral Palsy: A Randomized, Double-Blind Study of "High-Dose" versus "Low-Dose" Treatment*. <i>Neuropediatrics</i> , 1999, 30, 120-124.	0.3	122
565	Poor Response to Activated Protein C as a Prominent Risk Predictor of Advanced Atherosclerosis and Arterial Disease. <i>Circulation</i> , 1999, 99, 614-619.	1.6	60
566	Gait analysis to assess the effects of botulinum toxin type A treatment in cerebral palsy: an open-label study in 10 children with equinus gait pattern. <i>European Journal of Neurology</i> , 1999, 6, s63-s67.	1.7	12
567	Dopamine D4 receptor polymorphism and idiopathic Parkinson's disease. <i>European Journal of Human Genetics</i> , 1999, 7, 397-400.	1.4	10
568	Validation of a mail questionnaire for parkinsonism in two languages (German and Italian). <i>Journal of Neurology</i> , 1999, 246, 79-86.	1.8	31
569	Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint. <i>Movement Disorders</i> , 1999, 14, 911-913.	2.2	89
570	Reversible severe myopathy of respiratory muscles due to adult-onset type III glycogenosis. <i>Neuromuscular Disorders</i> , 1999, 9, 408-410.	0.3	23
571	Recent advances in the drug treatment of Parkinson's disease. <i>Current Opinion in Neurology</i> , 1999, 12, 411-415.	1.8	2
572	Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease. <i>Advances in Neurology</i> , 1999, 80, 545-8.	0.8	16
573	¹²³ I-β-CIT and ¹²³ I-β-BZM-SPECT scanning in levodopa-naive Parkinson's disease. <i>Movement Disorders</i> , 1998, 13, 438-445.	2.2	48
574	Cortical and brain stem hyperexcitability in striatonigral degeneration. <i>Movement Disorders</i> , 1998, 13, 602-607.	2.2	16
575	Cortical evoked potentials of the vesicourethral junction - a predictor for the outcome of intravesical electrostimulation in patients with sensory and motor detrusor dysfunction. <i>World Journal of Urology</i> , 1998, 16, 308-312.	1.2	17
576	Is EEG useful in the differential diagnosis of parkinsonism?. <i>Parkinsonism and Related Disorders</i> , 1998, 4, 79-80.	1.1	5

#	ARTICLE	IF	CITATIONS
577	The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease. <i>Clinical Neuropharmacology</i> , 1998, 21, 169-75.	0.2	27
578	Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes. <i>Journal of Nuclear Medicine</i> , 1998, 39, 954-60.	2.8	44
579	The role of insulin in age-related sex differences of cardiovascular risk profile and morbidity. <i>Atherosclerosis</i> , 1997, 130, 183-189.	0.4	16
580	Brain perfusion scintigraphy with ^{99m}Tc -HMPAO or ^{99m}Tc -ECD and ^{123}I - β -CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 320-325.	2.2	137
581	Tardive jaw tremor. <i>Movement Disorders</i> , 1997, 12, 460-462.	2.2	24
582	Body Iron Stores and the Risk of Carotid Atherosclerosis. <i>Circulation</i> , 1997, 96, 3300-3307.	1.6	316
583	Disturbance of time perception in left hemispheric migraine aura. <i>Journal of Neurology</i> , 1996, 243, 611-611.	1.8	1
584	Iodine-123-iodo-lisuride SPECT in Parkinson's disease. <i>Journal of Nuclear Medicine</i> , 1996, 37, 22-5.	2.8	9
585	Spasmodic torticollis - a multicentre study on behavioural aspects II: signs, symptoms and course. <i>Behavioural Neurology</i> , 1996, 9, 81-8.	1.1	3
586	Spasmodic torticollis - a multicentre study on behavioural aspects III: psychosocial changes and coping. <i>Behavioural Neurology</i> , 1996, 9, 89-95.	1.1	3
587	Spasmodic torticollis - a multicentre study on behavioural aspects IV: psychopathology. <i>Behavioural Neurology</i> , 1996, 9, 97-103.	1.1	4
588	Akathisia induced by necrosis of the basal ganglia after carbon monoxide intoxication. <i>Movement Disorders</i> , 1995, 10, 229-231.	2.2	13
589	Ischemic stress induces deposition of amyloid β immunoreactivity in human brain. <i>Acta Neuropathologica</i> , 1995, 90, 461-466.	3.9	149
590	Kava and dopamine antagonism.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1995, 58, 639-640.	0.9	102
591	Influence of Concurrent Tasks on Gait: A Dual-Task Approach. <i>Perceptual and Motor Skills</i> , 1995, 81, 107-113.	0.6	190
592	Fourth meeting of the European Neurological Society 25-29 June 1994 Barcelona, Spain. <i>Journal of Neurology</i> , 1994, 241, 1-164.	1.8	20
593	Dystonia in ataxia telangiectasia: Report of a case with putaminal lesions and decreased striatal [^{123}I]iodobenzamide Binding. <i>Movement Disorders</i> , 1994, 9, 455-459.	2.2	38
594	Perseverative motor behaviour in Parkinson's disease. <i>Neuropsychologia</i> , 1994, 32, 799-804.	0.7	21

#	ARTICLE	IF	CITATIONS
595	Dopamine D2 receptor imaging with iodine-123-iodobenzamide SPECT in idiopathic rotational torticollis. <i>Journal of Nuclear Medicine</i> , 1994, 35, 1921-7.	2.8	35
596	Current strategies in the drug treatment of advanced Parkinson's disease – new modes of dopamine substitution. <i>Acta Neurologica Scandinavica</i> , 1993, 87, 46-49.	1.0	5
597	Use of botulinum toxin in the treatment of cervical dystonia. <i>Baillière's Clinical Neurology</i> , 1993, 2, 179-85.	0.2	3
598	How to run a "brain bank"? Clinical and institutional requirements for "brain banking". <i>Journal of Neural Transmission Supplementum</i> , 1993, 39, 71-5.	0.5	3
599	IBZM-SPECT imaging in Parkinson's disease. Quantification of binding ratios from sequential SPECT measurements in patients and controls. <i>Advances in Neurology</i> , 1993, 60, 525-8.	0.8	3
600	Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients. <i>Advances in Neurology</i> , 1993, 60, 656-9.	0.8	29
601	Clinical features, diagnosis, and imaging of parkinsonian syndromes. <i>Current Opinion in Neurology and Neurosurgery</i> , 1993, 6, 333-8.	0.4	4
602	Clinical and polymyographic investigation of spasmodic torticollis. <i>Journal of Neurology</i> , 1992, 239, 9-15.	1.8	175
603	Treatment of spasmodic torticollis with local injections of botulinum toxin. <i>Journal of Neurology</i> , 1992, 239, 21-25.	1.8	103
604	Magnetic resonance imaging and angiography in hemifacial spasm. <i>Neuroradiology</i> , 1992, 34, 413-416.	1.1	46
605	Dystonia—a clinical, neuropathological and therapeutic review. <i>Journal of Neural Transmission Supplementum</i> , 1992, 38, 91-104.	0.5	5
606	Failure of oral administration of single rising doses of bromocriptine to produce acute anti-Parkinsonian effects.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1991, 54, 186-187.	0.9	2
607	Lack of selective vulnerability to anticholinergic induced cognitive impairment in early Parkinson's disease. <i>Behavioural Neurology</i> , 1991, 4, 103-11.	1.1	0
608	CSF somatostatin-like immunoreactivity in dementia of Parkinson's disease.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1990, 53, 1105-1106.	0.9	6
609	CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease. <i>Clinical Neuropharmacology</i> , 1990, 13, 303-11.	0.2	1
610	The premorbid personality of patients with Parkinson's disease: a comparative study with healthy controls and patients with essential tremor. <i>Advances in Neurology</i> , 1990, 53, 339-42.	0.8	29
611	APOMORPHINE TEST FOR DOPAMINERGIC RESPONSIVENESS. <i>Lancet, The</i> , 1989, 333, 1262-1263.	6.3	23
612	Pharmacological Study in Meige's Syndrome with Predominant Blepharospasm. <i>Clinical Neuropharmacology</i> , 1988, 11, 68-76.	0.2	22

#	ARTICLE	IF	CITATIONS
613	Visuoperception and visuospatial and visuorotational performance in Parkinson's disease. <i>Journal of Neurology</i> , 1987, 235, 99-101.	1.8	34
614	Dopaminergic-peptidergic interactions in extrapyramidal disorders: a review of the clinical evidence. <i>Advances in Neurology</i> , 1987, 45, 67-73.	0.8	0
615	Experience with selegiline in the treatment of Parkinson's disease. <i>Journal of Neural Transmission Supplementum</i> , 1987, 25, 131-5.	0.5	3
616	Foot dystonia in Parkinson's disease: clinical phenomenology and neuropharmacology. <i>Advances in Neurology</i> , 1987, 45, 357-60.	0.8	7
617	Psychometric findings in clinical subtypes of Parkinson's disease. <i>Advances in Neurology</i> , 1987, 45, 409-11.	0.8	1
618	Therapeutic experiences with an abeorphine derivative in Parkinson's disease. <i>Advances in Neurology</i> , 1987, 45, 591-2.	0.8	0
619	Separation from Mother at Time of Weaning. <i>Tropical Doctor</i> , 1986, 16, 176-177.	0.2	5
620	Prognostic implications of the motor symptoms of Parkinson's disease with respect to clinical, computertomographic and psychometric parameters. <i>Journal of Neural Transmission</i> , 1986, 67, 1-14.	1.4	12
621	KlÄ¼ver-Bucy syndrome in man: Experiences with posttraumatic cases. <i>Neuroscience and Biobehavioral Reviews</i> , 1983, 7, 413-417.	2.9	40
622	Premorbid personality of Parkinson patients. <i>Journal of Neural Transmission Supplementum</i> , 1983, 19, 215-24.	0.5	21
623	Myotonic myopathy with painful muscle contractions and decrease of symptoms by cold. <i>Journal of Neurology</i> , 1978, 219, 133-137.	1.8	1